Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
Securitize and Cantor Equity Partners II Business Combination Expected to Raise Approximately $400 million in Gross Proceeds and Announce Expected Closing of Business Combination and NYSE Listing